The Independent Cancer Research Foundation, Inc.

About the Independent Cancer Research Foundation, Inc.

The Independent Cancer Research Foundation was founded and is controlled by individuals who have a long history of being loyal to natural medicine research. Collectively, the board members have more than 25 years of experience researching and working with alternative cancer treatments. The members are hand-picked experts at treating cancer with natural substances or very low amperage electromedicine.

There are more than 300 alternative cancer treatments that are well documented. Several dozen of these treatments are highly effective cures, for most types of cancer, but they are cures for only "recently diagnosed" cancer patients who have not had extensive orthodox treatments, such as chemotherapy.

Only about a dozen of these treatments are highly effective for advanced cancer patients.

With this in mind, and if these cures are public information, why the need for the ICRF?

The research objectives of the ICRF are focused on helping advanced cancer patients, many of whom have been sent home to die by orthodox medicine. It is a universal constant that 95% of cancer patients who seek out alternative cancer treatments have already had extensive chemotherapy, radiation and surgery.

This kind of cancer patient is not only vulnerable to their cancer, but they are equally vulnerable to death caused by the damage done to their non-cancerous cells, their so-called "healthy" cells.

The focus of ICRF research will be on treatments which hopefully will not cause additional inflammation or swelling and will:
1) Protect with super-nutrients the non-cancerous cells,
2) Stop the spreading of cancer, and
3) Kill existing cancer cells or revert them into normal cells.

The ICRF board members already know how to do all of these things and are spreading the word about existing treatments for advanced cancer patients as much as time and money allow. Three of the board members have websites on alternative cancer treatments.

The Cellect-Budwig Protocol, the Bill Henderson Protocol and the perfection of the transdermal Chlorine-Dioxide/DMSO protocol were all developed by members of the ICRF. However, two of these three protocols cannot easily be used by cancer patients who are fed via feeding tube or by I.V.

Two new alternative cancer treatments, still under development, are being designed to be used by those being fed by feeding tube or I.V. One of these is the "Overnight Cure For Cancer," which is linked to at the bottom of this web page. The other treatment has not yet been protected, so we cannot mention it.

But these represent just two of the treatments we are researching for advanced cancer patients.

All of the cancer research charities and organizations on earth, including the oncologist-controlled American Cancer Society, and federal and educational researchers, cannot come close to the true cure rates of already existing ICRF-developed treatments!!

Yet, the funding of the ICRF has been less than 1/100,000th of 1% of all the other organizations!!

Current research involves the use of Cellect, chlorine dioxide (especially transdermally), DMSO, hydrogen peroxide (to shrink tumors), and several other treatment protocols.

Lab work can save us years of time isolating what works and what does not work. More importantly, lab work can confirm the safety of treatments very quickly. The ICRF already has a research lab committed to helping.

Next to treatments for advanced cancer patients, the next priority of the ICRF is to protect existing technologies from becoming extinct. At this point, we are not talking about technologies developed by ICRF board members.

There are several vulnerable technologies which are exceptional cancer treatments. For several different reasons these technologies are in danger of becoming extinct, as has happened already to many prior alternative cancer treatments (e.g. the Rife Machine was not protected before it was destroyed as a treatment, DMSO Potentiation Therapy was shut down by the FDA, etc. etc.).

There are some electromedicine treatments which the ICRF wants to purchase in order to protect their technology. Furthermore, we can learn how to use these technologies effectively and understand what makes them effective.

Protecting existing technologies also includes buying photographic equipment to photograph rare books, unique documents, etc. It also includes having extensive interviews with key people in their homes; such as Charlotte Gerson, Fred Eichhorn, Gaston Naessens and several others.

The ICRF already has in its possession several rare documents and knows where several others are located.

Much of the key foundation research for alternative cancer treatments was done back in the 1950s, 1960s, and 1970s. The Budwig protocol, Laetrile, DMSO, the Kelley Metabolic treatment, Essiac Tea, etc. all date to these time periods. Rare books from that time period need to be purchased or photographed. Some of them are so rare it will be hard to find them at all, much less purchase them. It took more than a year just to track down and obtain a book which had been published in 2001!! Older books can be even harder to find.

We know of, and are building relations with, several researchers who prefer to remain behind the curtain. Other researchers we do not know personally have been persecuted by the FDA and therefore do not trust anyone, including ICRF personnel. These researchers do not share their technologies; thus for all practical purposes, their technologies are already extinct thanks to persecution.

We also need to hire or encourage electrical engineers to design and build electromedicine devices to our specifications. This does not include the Rife Machine; which already has more than a hundred people researching it; but rather other electromedicine technologies which already have specifications proven to be effective. Currently, none of the existing products meet the correct specifications. In order for the ICRF to fund the development of these electromedicine devices, the ICRF would insist that either the schematics would be public domain, or the ICRF would have a copy of the schematics to protect the technology.

We need an office and a part time or full time office manager to answer emails (to free up the time of the researchers), handle company business, keep the two websites of the ICRF up to date, track down promising technologies, make appointments, coordinate research projects, etc. The Cancer Tutor website will be turned over to the ICRF and its office manager as soon as the necessary changes are made.

Should adequate funding ever become available, the ICRF would hire full time researchers to do much of the research of the organization. These will be employees of the ICRF, not contractors. Right now all research is being done by board members at no cost to the ICRF. Nevertheless, a great deal of highly effective research is going on!! Imagine how much more quality research can be done under more ideal circumstances, such as when travel is available!!

It is important to understand that we have found, while researching cancer, that several other key diseases have similar causes and/or similar treatments. It is critical to keep our eyes open when we run across research on other diseases, especially Lyme Disease, Multiple Sclerosis, Type 1 Diabetes (we already know how to cure Type 2 Diabetes), and other brain, chemical or microbe-caused diseases.

Finally, one long-term goal is to spread the word to people in hopes of getting people to use alternative cancer treatments much earlier in their treatment than they currently do. Curing someone recently diagnosed is many times easier than curing someone in hospice care.

It should also be understood by the reader that the ICRF is NOT in any way, shape or form, controlled by the pharmaceutical industry. This means that this organization is NOT looking for more profitable treatments for the pharmaceutical industry. We are not interested in turning cancer into a highly profitable chronic disease. We are looking for new cures for cancer.

Should those involved with the ICRF find one or more cures that meet the requirements they are looking for, the focus of the organization may switch from research to making this information public. Once the information is disseminated to their satisfaction, the organization may be dissolved or may continue to look for better cancer treatments or may look for treatments for other diseases.

Who Are the Members of the Board of Directors

Here are the current officers and members of the Board of Directors:

R. Webster Kehr, President, author of the Cancer Tutor website. Webster lives in Kansas.

Mike Vrentas, Vice President - Treasurer, who with his wife Cherie, run a small natural medicine website. Mike lives in Missouri.

Bill Henderson, Vice President - Secretary, is the author of a major book on alternative cancer treatments. He is also the author of a major website on cancer. Bill lives in North Carolina.

Dr. William Wassell, M.D., Vice President, is active in Vitamin C research (i.e. orthomolecular medicine) and provides technical support for alternative cancer researchers. Dr. Wassell lives in Louisiana.

Gary Teal, Board Member, is an expert in acupuncture, electromedicine and general alternative cancer treatments. Gary lives in Utah.

Collectively, the members of the board have more than 25 years of alternative cancer treatment research. All of them want to see cancer cured and all of them have made contributions to that end.

How Do I Contribute to the ICRF?

The ICRF is a non-profit corporation, incorporated in the state of Nevada. The ICRF is tax-exempt under Section 501(c)(3) of the Internal Revenue Code and is classified as a "public charity" [170(b)(1)(A)(vi)]. Those who make contributions to the ICRF may take a tax-deduction under Section 170 of the Code. The advance ruling is valid until December 31, 2010, when it will be reviewed by the IRS.

The tax number of the ICRF is: 20-4461836

Contributions are greatly appreciated and can be sent to:

Independent Cancer Research Foundation, Inc.
P.O. 2074
Lees Summit, MO 64063

To email the ICRF:
Email ICRF